Nothing Special   »   [go: up one dir, main page]

BR112019002579A2 - anticorpos biespecíficos fab monovalentes, assimétricos e tandem - Google Patents

anticorpos biespecíficos fab monovalentes, assimétricos e tandem

Info

Publication number
BR112019002579A2
BR112019002579A2 BR112019002579-0A BR112019002579A BR112019002579A2 BR 112019002579 A2 BR112019002579 A2 BR 112019002579A2 BR 112019002579 A BR112019002579 A BR 112019002579A BR 112019002579 A2 BR112019002579 A2 BR 112019002579A2
Authority
BR
Brazil
Prior art keywords
asymmetric
antibodies
monovalent
bispecific antibodies
fab bispecific
Prior art date
Application number
BR112019002579-0A
Other languages
English (en)
Inventor
Wu Chengbin
Original Assignee
Epimab Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimab Biotherapeutics, Inc. filed Critical Epimab Biotherapeutics, Inc.
Publication of BR112019002579A2 publication Critical patent/BR112019002579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a invenção propõe anticorpos biespecíficos fab monovalen tes, assimétricos e tandem que podem ligar dois epítopos ou dois antígenos, composições que compreendem esses anticorpos, usos desses anticorpos, métodos para produzir esses anticorpos, ácidos nucleicos que codificam esses anticorpos e células hospedeiras que compreendem esses ácidos nucleicos.
BR112019002579-0A 2016-08-16 2017-08-15 anticorpos biespecíficos fab monovalentes, assimétricos e tandem BR112019002579A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016095546 2016-08-16
CNPCT/CN2016/0095546 2016-08-16
CN2016109267 2016-12-09
CNPCT/CN2016/0109267 2016-12-09
PCT/US2017/046875 WO2018035084A1 (en) 2016-08-16 2017-08-15 Monovalent asymmetric tandem fab bispecific antibodies

Publications (1)

Publication Number Publication Date
BR112019002579A2 true BR112019002579A2 (pt) 2019-05-21

Family

ID=61197005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002579-0A BR112019002579A2 (pt) 2016-08-16 2017-08-15 anticorpos biespecíficos fab monovalentes, assimétricos e tandem

Country Status (10)

Country Link
US (1) US20190177439A1 (pt)
EP (1) EP3500301B1 (pt)
JP (1) JP7033328B2 (pt)
CN (1) CN109803682B (pt)
AU (1) AU2017312974B2 (pt)
BR (1) BR112019002579A2 (pt)
CA (1) CA3032430A1 (pt)
ES (1) ES2963385T3 (pt)
TW (1) TWI672317B (pt)
WO (1) WO2018035084A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020010077A1 (en) * 2018-07-03 2020-01-09 Ngm Biopharmaceuticals, Inc. Bispecific antibodies
PE20211867A1 (es) * 2018-11-01 2021-09-21 Shandong New Time Pharmaceutical Co Ltd Anticuerpos biespecificos y su uso
US11965030B2 (en) 2018-12-24 2024-04-23 Sanofi Multispecific binding proteins with mutant fab domains
CN111378044B (zh) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
CN109942712B (zh) * 2019-04-01 2022-12-20 华博生物医药技术（上海）有限公司 抗pd-l1/vegf双功能抗体及其用途
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
MX2022006230A (es) * 2019-11-26 2022-06-22 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
WO2021143826A1 (zh) * 2020-01-17 2021-07-22 信达生物制药(苏州)有限公司 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途
IL295896A (en) 2020-02-26 2022-10-01 Biograph 55 Inc c19 c38 bispecific antibodies
TWI838621B (zh) * 2020-04-29 2024-04-11 美商泰尼歐萬公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
WO2022037582A1 (zh) * 2020-08-18 2022-02-24 上海君实生物医药科技股份有限公司 抗cd3和抗cldn-18.2双特异性抗体及其用途
JP2023538945A (ja) * 2020-08-24 2023-09-12 エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
CA3235018A1 (en) * 2021-10-15 2023-04-20 Leila M. BOUSTANY Activatable polypeptide complex
JP2024539650A (ja) * 2021-10-15 2024-10-29 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能なポリペプチド複合体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
WO2001077342A1 (en) * 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1297172B1 (en) 2000-06-28 2005-11-09 Glycofi, Inc. Methods for producing modified glycoproteins
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
EP2484774A3 (en) * 2005-07-21 2012-11-14 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG10201604699VA (en) * 2010-12-21 2016-07-28 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
LT2748202T (lt) * 2011-08-23 2018-09-25 Roche Glycart Ag Bispecifinės antigeną surišančios molekulės
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
RU2769133C2 (ru) 2013-12-30 2022-03-28 Эпимаб Биотерапьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
WO2015134411A1 (en) * 2014-03-03 2015-09-11 Academia Sinica Bi-specific antibodies and uses thereof
PL3608337T3 (pl) * 2014-08-04 2024-07-22 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujący limfocyty T
AR101875A1 (es) * 2014-09-15 2017-01-18 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
PT3212226T (pt) * 2014-10-31 2020-06-22 Ngm Biopharmaceuticals Inc Composições e métodos de utilização para tratamento de distúrbios metabólicos
EP3747905A1 (en) * 2014-11-20 2020-12-09 F. Hoffmann-La Roche AG Common light chains and methods of use
JP2023538945A (ja) * 2020-08-24 2023-09-12 エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質

Also Published As

Publication number Publication date
AU2017312974B2 (en) 2024-03-21
EP3500301B1 (en) 2023-08-30
JP2019533985A (ja) 2019-11-28
RU2019103230A3 (pt) 2020-11-30
AU2017312974A1 (en) 2019-02-21
TW201808999A (zh) 2018-03-16
CA3032430A1 (en) 2018-02-22
WO2018035084A8 (en) 2023-08-10
TWI672317B (zh) 2019-09-21
CN109803682A (zh) 2019-05-24
JP7033328B2 (ja) 2022-03-10
US20190177439A1 (en) 2019-06-13
CN109803682B (zh) 2024-07-19
RU2019103230A (ru) 2020-09-18
EP3500301A1 (en) 2019-06-26
ES2963385T3 (es) 2024-03-26
EP3500301A4 (en) 2020-04-22
WO2018035084A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
BR112019002579A2 (pt) anticorpos biespecíficos fab monovalentes, assimétricos e tandem
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
BR112018008904A2 (pt) anticorpos que se ligam especificamente a tim-3 e seus usos
UA117289C2 (uk) Мультиспецифічне антитіло
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
CL2020000920A1 (es) Anticuerpo monoclonal anti-il-5ra.
EA201892124A1 (ru) Днк-конструкции антител и способы их применения

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements